Monoclonal antibody therapy and renal transplantation: focus on adverse effects (Q26826880)

26 October 2020

kidney transplantation

1 reference

24 January 2021

Gianluigi Zaza

1

1 reference

Paola Tomei

2

1 reference

Simona Granata

3

1 reference

Luigino Boschiero

4

1 reference

Antonio Lupo

5

1 reference

language of work or name

1 reference

28 February 2014

8 references

1 July 2019

25 June 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

24 January 2021

8 references

1 July 2019

25 June 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

24 January 2021

6

1 reference

page(s)

869-91

1 reference

issue

3

1 reference

Creative Commons Attribution

copyright license

7 references

1 July 2019

25 June 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

24 January 2021

0 references

Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Eculizumab for dense deposit disease and C3 glomerulonephritis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Immunotherapy: past, present and future

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rituximab in renal transplantation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Long-term outcome of adults who undergo transplantation with single pediatric kidneys: how young is too young?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Eculizumab in renal transplantation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

The use of eculizumab in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

The role of complement in antibody-mediated rejection in kidney transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rituximab-induced thrombocytopenia: a cohort study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Non-infectious pulmonary toxicity of rituximab: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Neutropenia after rituximab treatment: new insights on a late complication

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Calcineurin inhibitors in kidney transplantation: friend or foe?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Alemtuzumab induction in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Induction immunosuppressive therapies in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

T-cell alloimmunity and chronic allograft dysfunction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Neutropenia associated with rituximab therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rituximab-associated infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

KDIGO clinical practice guideline for the care of kidney transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Campath induction for kidney transplantation: report of 297 cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rituximab-induced acute thrombocytopenia: a case report and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Induction therapy in renal transplantation : an overview of current developments

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Cytokine-release syndrome: overview and nursing implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

The role of basiliximab induction therapy in organ transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Immunosuppressive drug-induced diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Current and future immunosuppressive strategies in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Multivariate analyses of antibody induction therapies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Basiliximab: a review of its use as induction therapy in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Controversies in lung transplantation: management of cytomegalovirus infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Alemtuzumab: a novel monoclonal antibody

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A review of interleukin-2 receptor antagonists in solid organ transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Mechanisms of action and overview of OKT3.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Monoclonal antibodies in renal transplantation: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Complement activation determines the therapeutic activity of rituximab in vivo.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Quantitative characterization of the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its modulation by the alpha chain and a second affinity-modulating element.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Anaphylactic shock after retreatment with OKT3 monoclonal antibody

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Induction of thromboses within renal grafts by high-dose prophylactic OKT3

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Cytomegalovirus infection during OKT3 treatment for renal allograft rejection

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A Randomized Prospective Trial of Acyclovir and Immune Globulin Prophylaxis in Liver Transplant Recipients Receiving OKT3 Therapy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Prediction of successful allograft rejection retreatment with OKT3

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers

31 May 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Trends in organ donation and transplantation in the United States, 1999-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Long-term outcome of highly sensitized African American patients transplanted with deceased donor kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Alemtuzumab induction in deceased donor kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Cancer risk with alemtuzumab following kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Impact of rituximab therapy for treatment of acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Treatment of PTLD with rituximab or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

FDA: Increased HBV reactivation risk with ofatumumab or rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Meningococcal sepsis complicating eculizumab treatment despite prior vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

The UNOS Renal Transplant Registry.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Encephalopathy following the use of OKT3 in renal allograft transplantation.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

Nosocomial aseptic meningitis associated with administration of OKT3

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968366

A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

28 November 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS6030869

Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators

21 January 2018

1 reference

12 December 2020

Activation of coagulation and fibrinolysis during treatment with OKT3

1 reference

12 December 2020

Evaluation of low-dose rituximab induction therapy in living related kidney transplantation

1 reference

12 December 2020

Rituximab-induced coagulopathy

1 reference

12 December 2020

Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation--single-center study

1 reference

12 December 2020

Improved graft survival after renal transplantation in the United States, 1988 to 1996

1 reference

12 December 2020

Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients

1 reference

12 December 2020

Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

1 reference

12 December 2020

Monoclonal antibodies in renal transplantation: old and new

1 reference

12 December 2020

Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses

1 reference

12 December 2020

Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells

1 reference

12 December 2020

Recurrent bacterial meningitis in patients with genetic defects of terminal complement components

1 reference

12 December 2020

Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression

1 reference

12 December 2020

Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

12 December 2020

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies

1 reference

12 December 2020

Complement activation during OKT3 treatment: a possible explanation for respiratory side effects

1 reference

12 December 2020

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 reference

12 December 2020

Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up

1 reference

12 December 2020

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

12 December 2020

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients

1 reference

12 December 2020

Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation

1 reference

12 December 2020

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients

1 reference

12 December 2020

Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up

1 reference

12 December 2020

Long-term results of rabbit antithymocyte globulin and basiliximab induction

1 reference

12 December 2020

Identifiers

DOI

10.3390/TOXINS6030869

1 reference

release_fxvh4l3fabfxnbufdmgbys4gg4

3387404

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fxvh4l3fabfxnbufdmgbys4gg4

24 November 2022

mapped directly with Wikidata item

3387404

1 reference

1 reference

1 reference